Literature DB >> 22966253

Original and infiltrating patterns of prostatic carcinoma.

Nobuki Furubayashi1, Motonobu Nakamura, Keniti Nishiyama, Yoshihiro Hasegawa.   

Abstract

In order to demonstrate the original and infiltrating patterns of prostatic carcinoma, the change of histological characteristics associated with increasing total cancer volume was investigated. Tissue specimens from 196 histopathological cases, obtained at the Kyushu Cancer Center, were reviewed in embedded whole-mount antegrade radical prostatectomy specimens with adenocarcinoma. Three groups (<0.5 cm(3), ≤0.5 cm(3) <1 cm(3) and ≥1 cm(3)) of total cancer volume were identified and a histological study on each group was conducted based on the 2005 International Society of Urological Pathology Consensus Conference on Gleason Grading of Prostatic Carcinoma. With a cancer volume of <0.5 cm(3), Gleason primary patterns 3 and 4 were observed in 64.4 and 26.7% of the tumors, respectively, while Gleason secondary patterns 3 and 4 were observed in 53.3 and 42.2%, respectively. The density of the acini was much higher in comparison with that of ambient normal acini. The percentage of acini, including cribriform carcinoma classified as Gleason pattern 3, increased significantly with the increase of cancer volume (p<0.01). The original pattern of the prostatic carcinoma was histologically composed of small acini of Gleason patterns 3 and 4 without forming a cribriform pattern. In addition, prostatic carcinoma infiltrated the surrounding stroma at a very early stage, thus infiltrating not only the stroma but also the preexisting ducts and acini, causing an increased cancer volume.

Entities:  

Year:  2010        PMID: 22966253      PMCID: PMC3436381          DOI: 10.3892/ol_00000007

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  10 in total

Review 1.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Authors:  Jonathan I Epstein; William C Allsbrook; Mahul B Amin; Lars L Egevad
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

2.  Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate.

Authors:  J E McNeal; A A Villers; E A Redwine; F S Freiha; T A Stamey
Journal:  Cancer       Date:  1990-09-15       Impact factor: 6.860

3.  Ductal spread in prostatic carcinoma.

Authors:  J Kovi; M A Jackson; M Y Heshmat
Journal:  Cancer       Date:  1985-10-01       Impact factor: 6.860

4.  Classification of prostatic carcinomas.

Authors:  D F Gleason
Journal:  Cancer Chemother Rep       Date:  1966-03

5.  Survival rates of patients with prostatic cancer, tumor stage, and differentiation--preliminary report.

Authors:  J C Bailar; G T Mellinger; D F Gleason
Journal:  Cancer Chemother Rep       Date:  1966-03

6.  The histology and prognosis of prostatic cancer.

Authors:  G T Mellinger; D Gleason; J Bailar
Journal:  J Urol       Date:  1967-02       Impact factor: 7.450

7.  Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens--a different view.

Authors:  A A Elgamal; H P Van Poppel; W M Van de Voorde; J A Van Dorpe; R H Oyen; L V Baert
Journal:  J Urol       Date:  1997-01       Impact factor: 7.450

8.  Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations.

Authors:  J E McNeal; C E Yemoto
Journal:  Am J Surg Pathol       Date:  1996-07       Impact factor: 6.394

9.  Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer.

Authors:  T A Stamey; F S Freiha; J E McNeal; E A Redwine; A S Whittemore; H P Schmid
Journal:  Cancer       Date:  1993-02-01       Impact factor: 6.860

10.  Cribriform adenocarcinoma of the prostate.

Authors:  J E McNeal; J H Reese; E A Redwine; F S Freiha; T A Stamey
Journal:  Cancer       Date:  1986-10-15       Impact factor: 6.860

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.